Our Journey
Take a look at our journey of creating the first comprehensive AI diagnostic solutions.
Mediwhale’s most defining moments
2023
August
Presented the research results at the 2023 European Society of Cardiology (ESC) conference
Awarded 3rd place in the Myoptic Maculopathy Analysis Challenge(MMAC) hosted by The Medical Image Computing and Computer Assisted Intervention(MICCAI)
Reti-CKD was designated as the Innovative Medical Device by the Ministry of Food and Drug Safety of Korea
June
Emerged as the winner of the ‘CKD Challenge’ organized by AstraZeneca with the collaboration of Wayra
Proof of concept paper for Reti-CKD was published in the npj Digital Medicine(IF 15.357), a portfolio journal of the Nature
Physicians can charge patients for Reti-CVD for diagnosis and treatment purposes as it was selected for the Postponement of New Health Technology Assessment (nHTA)
March
Raises $9 million Series A round for AI-empowered eye scans predicting future diseases
Joined the MedTech Accelerator program at Mayo Clinic and Arizona State University
January
Joined StartX, a prestigious Silicon Valley-based accelerator program affiliated with Stanford University and Stanford Healthcare
2022
November
Awarded CES Innovation Award 2023 for Reti-CVD
Presented at the American Heart Association (AHA) Scientific Session in Chicago and the American Society of Nephrology’s (ASN) Kidney Week in Orlando, Florida
Reti-CVD was confirmed to be the candidate of the New Health Technology Assessment (nHTA) by the HIRA (Health Insurance Review and Assessment Service) in Korea, meaning it is a new medical practice that requires separate compensation by the Korean national insurance
October
Selected in HeartX 2022, a cardiovascular-focused healthcare accelerator program supported by HealthTech Arkansas and MedAxiom
Joined Innovator’s Network of Center for Health Technology & Innovation at the American Heart Association
August
Reti-CVD was approved as a class III medical device by the Ministry of Food and Drug Safety of Korea
June
Reti-Eye was installed in Cheonho public health clinic in Seoul as part of a metabolic disease prevention campaign
April
“Retinal photograph-based deep learning predicts biological age, and stratifies morbidity and mortality risk” was published in the peer-reviewed medical journal, Age and Ageing (IF:12.8)
Reti-Eye & Reti-CVD were registered as class IIa medical devices by the National Agency of Drug and Food Control (NA-DFC) of Indonesia – Category: Cardiovascular risk assessment based on retinal image & eye screening service
February
Singapore office was opened
Reti-Eye & Reti-CVD were registered as a medical device by Medicines and Healthcare products Regulatory Agency of UK – Category: Cardiovascular risk assessment based on retinal image & eye screening service
January
Reti-Eye was registered as a medical device by the Health Science Authority (HSA) of Singapore – Category: Cardiovascular risk assessment based on retinal image & eye screening service
2021
December
Reti-Eye & Reti-CVD were registered as a class IIa medical device by the Australian Registry of Therapeutic Goods (ARTG)
Reti-Eye & Reti-CVD were registered as class B medical devices by Health Sciences Authority (HSA) of Singapore
October
Reti-Eye & Reti-CVD were registered as class B medical devices by the Ministry of Health of Malaysia
August
Raised $2 mil Pre-A round from Korean investors led by SBI Investment
A patent “AI technology that predicts cardiovascular disease risk through retinal image” was transferred from Singapore Eye Center
May
Reti-Eye & Reti-CVD obtained CE approval as a class IIa medical device in the EU – Category: Cardiovascular risk assessment based on retinal image & eye screening service
“Deep-learning-based cardiovascular risk stratification using coronary artery calcium scores predicted from retinal photographs” was published in a top-tier medical journal (The Lancet Digital Health, IF:36.6)
2020
December
Reti-CVD was registered as an innovative medical device by the Ministry of Food and Drug Safety of Korea for screening cardiovascular risk
November
“Prediction of systemic biomarkers from retinal photographs: development and validation of deep-learning algorithms” was published in a top-tier medical journal (The Lancet Digital Health, IF: 36.6)
August
Reti-Eye was approved as a class III medical device by the Ministry of Food and Drug Safety of Korea
May
ISO 13485 certification was obtained
2019
July
A research collaboration agreement was signed with Singapore Eye Research Institute (SERI)
March
KGMP (Korean Good Manufacturing Practice) certificate was obtained
February
8 patented technologies were transferred from Yonsei University including “Retinal image analysis method” and “Cardiovascular disease diagnosis through retinal image”
2018
August
A research collaboration agreement was signed with Yonsei University Health System to develop AI-based eye screening technology through retinal image analysis
March
“Retinal image analysis method” technologies were transferred from Yonsei University
2017
September
A leadership team of Kevin Taegeun Choi, Tyler Hyungtaek Rim, and Young Geunyoung Lee was formed
MARCH
2nd place was awarded in the biggest medical data analysis competition hosted by Asan Medical Center & Microsoft Korea
2016
December
Mediwhale Inc. was founded in Seoul, Korea